1,106 material Form 8-K filings that 909 companies we cover made with the SEC in June 2026, each read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). All of them were written later, when past filings were added: a selection, not every 8-K of the month (see the note below).
Research Frontiers received two Nasdaq deficiency letters on June 2, 2026, saying its stock has closed below the $1.00 minimum bid price and its market value of listed securities has fallen below $35 million. The company has until November 30, 2026 to regain compliance, and the stock continues to trade on the Nasdaq Capital Market under REFR, but there is no assurance it will regain compliance.
Bid price notice: closing bid below $1.00 for 30 consecutive business days from April 15 to June 1, 2026
MVLS notice: market value of listed securities below $35 million for 30 consecutive business days from April 20 to June 1, 2026
Compliance deadline: November 30, 2026; regaining compliance requires ten consecutive business days at or above the thresholds
The company does not currently intend to effect a reverse stock split to regain compliance
Alphabet sold two series of mandatory convertible preferred stock through depositary shares, with the offerings closing on June 5, 2026. The preferred pays a 6.25% dividend and converts into Class A or Class C common stock around May 15, 2029, which could add new shares to the count, while dividends on common stock are restricted until accumulated preferred dividends are paid.
Series A and Series B each had 167.5 million depositary shares sold, plus up to 25 million additional shares per series under over-allotment options that underwriters exercised in full on June 3, 2026.
Each depositary share is a 1/20th interest in a preferred share with a $1,000 liquidation preference; dividends are 6.25% per year, payable quarterly from August 15, 2026 through May 15, 2029.
Preferred shares convert on or about May 15, 2029 into between 2.2520 and 2.8160 Class A shares (Series A) and between 2.2740 and 2.8420 Class C shares (Series B), subject to adjustments.
While preferred stock is outstanding, no common stock dividends or buybacks are allowed unless accumulated preferred dividends have been paid; capped call cap prices are $532.6704 (Series A) and $527.7974 (Series B).
Dream Finders Homes appointed Clint Szubinski as Chief Operating Officer effective immediately, with an employment agreement that includes an $800,000 base salary and a $6,000,000 restricted stock signing bonus. Doug Moran, formerly COO, is now National President and will continue to provide guidance, and Szubinski will direct the Company's strategic vision and operational performance.
Appointment announced June 1, 2026; effective immediately
Base salary of $800,000 and one-time signing bonus of restricted stock valued at $6,000,000, vesting annually over three years
Szubinski previously served as Chief Operating Officer and Executive Vice President of Meritage Homes Corporation from January 2021 to May 2025
Severance includes 12 months of base salary if terminated without Cause during the first three years
LCI Industries said CEO Jason Lippert retired and left the Board effective June 3, 2026, and Board Chair Tracy Graham also resigned from the Board. Director John A. Sirpilla was appointed interim CEO, and the Board will search for a permanent CEO, which means the company has no permanent chief executive for now.
Jason Lippert retired as CEO and resigned from the Board effective June 3, 2026; the filing says the departure did not result from any disagreement with the company.
John A. Sirpilla became interim CEO effective immediately, with a base salary of $1,100,000 and a target bonus of 140% of base salary.
Sirpilla received a one-time RSU grant with a grant-date value of $1,800,000, and Lippert will receive $100,000 per month for consulting services through June 3, 2027.
Virginia Henkels was named Board Chair, and Stephanie K. Mains became Audit Committee Chair, both effective June 3, 2026.
OptimizeRx said Chief Commercial Officer Theresa Greco will leave the role effective June 15, 2026, under a separation agreement, and will then serve as an advisor through June 15, 2027. The filing says the agreement provides 12 months of base salary at $380,000 per year, a $209,000 lump-sum bonus, and COBRA premium reimbursement, which shareholders may track as a cost of the executive transition.
Theresa Greco's separation is effective June 15, 2026; the separation agreement was signed June 1, 2026 and becomes enforceable June 9, 2026, absent revocation.
Greco will receive 12 months of base salary at $380,000 per year, a $209,000 lump-sum payment of her annual cash bonus target, and COBRA premium reimbursement for 12 months.
Greco will serve as an advisor for 12 months through June 15, 2027, with equity previously granted continuing to vest; she is also subject to 12-month non-compete and non-solicitation terms.
The full agreement will be filed as an exhibit to the Form 10-Q for the quarter ending June 30, 2026.
FMC completed a $1.2 billion private offering of 8.000% senior secured notes maturing June 1, 2031, with net proceeds estimated at about $1.185 billion. The company plans to use the proceeds to repurchase or redeem its 3.200% notes due October 1, 2026, repay credit agreement borrowings, and for general corporate purposes, so shareholders will see a larger secured debt load at a higher interest rate.
$1.2 billion aggregate principal of 8.000% senior secured notes due June 1, 2031, issued at 100% of principal
Estimated net proceeds of approximately $1.185 billion after discounts, commissions and offering expenses
Proceeds intended to fund repurchase or redemption of 3.200% senior notes due October 1, 2026, and repay borrowings under the credit agreement dated June 17, 2022
Notes are secured by first-priority liens on substantially all assets of U.S., Canadian and Swiss guarantor entities, plus equity interests of Singapore and Netherlands subsidiaries
G-III Apparel reported first-quarter fiscal 2027 net sales down 8% to $536.0 million, while GAAP net income rose to $66.5 million, or $1.50 per diluted share, helped by a $102.7 million pre-tax benefit from expected recovery of IEEPA tariffs. The company raised its fiscal 2027 net income guidance, but its non-GAAP net loss of $0.21 per share and its lower-sales outlook show the profit gain depends heavily on the one-time tariff item.
Net sales fell 8% to $536.0 million from $583.6 million a year earlier.
GAAP net income was $66.5 million, or $1.50 per diluted share, versus $7.8 million, or $0.17, last year.
Non-GAAP net loss was $0.21 per share, compared with non-GAAP earnings of $0.19 per share last year.
Fiscal 2027 GAAP net income is now expected at $171.0 million to $175.0 million; second-quarter net income is expected at $7.0 million to $11.0 million.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Briefs marked “Written later” were written in November 2026 for filings that were by then more than three weeks old, so months before mid-October 2026 hold a selection: every material 8-K of the past year for the 100 largest companies we cover and the last 15 important 8-Ks of every other one. Briefs the number check holds back are not shown or counted. Also: the last 45 days, briefs by company, A–Z and the live SEC filings wire.